GLUT1 transporter-facilitated solid lipid nanoparticles loaded with anti-cancer therapeutics for ovarian cancer targeting
Related Experiment Video
Updated: Aug 5, 2025
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Saili Jagdale1, Mahavir Narwade1, Afsana Sheikh2
1Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth, Pune, India.
Abstract:
The therapeutics available for cancer treatment have the major hurdle of site-specific delivery of anti-cancer drugs to the tumor site and non-target specific side effects. The standard therapy for ovarian cancer still poses numerous pitfalls due to the irrational use of drugs affecting healthy cells. As an appealing approach, nanomedicine could revamp the therapeutic profile of anti-cancer agents. Owing to the low manufacturing cost, increased biocompatibility, and modifiable surface properties, lipid-based nanocarriers, particularly solid lipid nanoparticles (SLN), have remarkable drug delivery properties in cancer treatment. Given the extra-ordinary benefits, we developed anti-neoplastic (paclitaxel) drug-loaded SLN (PTX-SLN) and functionalized with N-acetyl-d-glucosamine (GLcNAc) (GLcNAc-PTX-SLN) to reduce the rate of proliferation, growth, and metastasis of ovarian cancer cells over-expressing GLUT1 transporters. The particles presented considerable size and distribution while demonstrating haemocompatibility. Using GLcNAc modified form of SLNs, confocal microscopy, MTT assay, and flow cytometry study demonstrated higher cellular uptake and significant cytotoxic effect. Also, molecular docking results established excellent binding affinity between GLcNAc and GLUT1, complimenting the feasibility of the therapeutic approach in targeted cancer therapy. Following the compendium of target-specific drug delivery by SLN, our results demonstrated a significant response for ovarian cancer therapy.
Insights
Targeted ovarian cancer therapy is improved using N-acetyl-d-glucosamine functionalized solid lipid nanoparticles (SLN) loaded with paclitaxel. This nanomedicine approach enhances drug delivery and reduces side effects for better treatment outcomes.
Area of Science:
- Nanomedicine
- Oncology
- Drug Delivery Systems
Background:
- Current cancer therapeutics face challenges with site-specific drug delivery and off-target side effects.
- Ovarian cancer treatment is hampered by conventional drug administration affecting healthy cells.
- Nanomedicine offers a promising strategy to enhance the therapeutic efficacy of anti-cancer agents.
Purpose of the Study:
- To develop and evaluate N-acetyl-d-glucosamine functionalized solid lipid nanoparticles (GLcNAc-PTX-SLN) for targeted ovarian cancer therapy.
- To investigate the cellular uptake and cytotoxic effects of GLcNAc-PTX-SLN on ovarian cancer cells over-expressing GLUT1.
- To assess the binding affinity between N-acetyl-d-glucosamine and GLUT1 for targeted drug delivery.
Main Methods:
- Preparation and characterization of paclitaxel-loaded solid lipid nanoparticles (PTX-SLN) functionalized with N-acetyl-d-glucosamine (GLcNAc-PTX-SLN).
- Evaluation of particle size, distribution, and haemocompatibility.
- Assessment of cellular uptake using confocal microscopy and cytotoxicity via MTT assay and flow cytometry.
- Molecular docking studies to determine binding affinity between GLcNAc and GLUT1.
Main Results:
- GLcNAc-PTX-SLN exhibited favorable particle characteristics and haemocompatibility.
- Enhanced cellular uptake and significant cytotoxic effects were observed with GLcNAc-PTX-SLN compared to unmodified SLN.
- Molecular docking confirmed strong binding affinity between GLcNAc and GLUT1, validating the targeted delivery approach.
- The developed nanoparticles demonstrated a significant therapeutic response in ovarian cancer models.
Conclusions:
- Functionalized solid lipid nanoparticles represent an effective platform for targeted ovarian cancer therapy.
- GLcNAc modification enhances the delivery and efficacy of paclitaxel in GLUT1-over-expressing ovarian cancer cells.
- This nanomedicine approach holds potential for reducing side effects and improving treatment outcomes in ovarian cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:06Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...